Femasys Announces Financial Results for Quarter Ended March 31, 2025, and Provides Corporate Update
- European regulatory approval secured for FemBloc delivery system
- 78% quarter-over-quarter sales increase for FemaSeed in the U.S.
- Overall sales growth of 25.9% year-over-year
- Strategic partnership with CNY Fertility's eleven centers
- UK and Israeli regulatory approvals obtained for FemaSeed
- Net loss increased by 63.8% to $5.9 million
- R&D expenses increased by 67.6% to $3.0 million
- Current cash expected to fund operations only until early Q3 2025
- Accumulated deficit of $133.1 million
- Significant increase in operating expenses across all categories
Insights
Femasys shows product progress but faces critical cash concerns with only one quarter of runway remaining.
Femasys's Q1 2025 financial results present a 25.9% year-over-year revenue growth to
R&D costs increased
The most concerning metric is Femasys's cash position of just
While regulatory approvals and new partnerships demonstrate business development progress, the financial fundamentals reveal a company still in early commercialization with an accelerating burn rate rather than improving financial metrics. The quarterly cash burn appears to be increasing as Femasys invests in growth initiatives, creating tension between product advancement and financial sustainability.
Femasys secures critical European regulatory milestones for female contraception while advancing multi-market commercialization strategy.
Femasys has achieved significant regulatory milestones that substantially advance its women's health portfolio. Most notably, the company secured its first global regulatory approval for the FemBloc permanent birth control delivery system in Europe, successfully completing the demanding G12 Special MDR Audit for Class III devices – the highest risk classification under European regulations. The FemBloc polymer component received Notified Body recommendation for CE mark approval, with only final European Medical Agency review pending.
The regulatory momentum extends beyond FemBloc, with United Kingdom and Israeli authorities approving both FemaSeed (first-line infertility treatment) and two diagnostic devices. These multi-market authorizations demonstrate regulatory confidence in Femasys's technology platform across different geographies.
The company is executing a methodical commercialization strategy, evidenced by the partnership with CNY Fertility's eleven fertility centers for FemaSeed distribution and establishing distribution channels for FemBloc in Spain. The positive safety and efficacy results from FemBloc clinical trials published in peer-reviewed literature strengthen the product's clinical foundation.
Intellectual property protection has also advanced with notices of intention to grant two European patent applications for FemBloc and a notice of allowance for a new U.S. patent application for FemaSeed. These regulatory achievements and early commercial traction (
-- Company delivers on mission to transform women’s health with innovative solutions, including FemaSeed® for first-line infertility treatment and FemBloc® non-surgical permanent birth control (full system approval pending in Europe) --
ATLANTA, May 08, 2025 (GLOBE NEWSWIRE) -- Femasys Inc. (NASDAQ: FEMY), a leading biomedical innovator addressing significant unmet needs in women’s health worldwide, with a broad portfolio of disruptive, accessible, in-office therapeutic and diagnostic products, announces financial results for the quarter ended March 31, 2025 and provides a corporate update.
Corporate Highlights from 1Q 2025 to date
- Announced FemBloc permanent birth control delivery system approval in Europe; FemBloc blended polymer component successfully completed an expedited G12 Special MDR Audit for Class III devices, and the Notified Body has recommended for CE mark approval pending the final stages of European Medical Agency (EMA) review
- Announced United Kingdom and Israeli regulatory approvals for FemaSeed and two diagnostic devices
- Announced partnership with CNY Fertility, a national conglomerate of eleven fertility centers, to offer FemaSeed
- Announced distribution partnerships for FemBloc in Spain
- Announced peer-reviewed publication of positive safety and efficacy results from FemBloc clinical trials
- Announced notices of intention to grant two new European patent applications for FemBloc
- Announced notice of allowance for new U.S. patent application for FemaSeed
“Securing the first regulatory approval globally for the FemBloc delivery system marks a key milestone toward full system approval and the introduction of a first-of-its-kind, non-surgical permanent birth control option for women in Europe,” said Femasys’ CEO Kathy Lee-Sepsick. “Additionally in the first quarter of 2025, we began executing our commercialization strategy for FemaSeed, achieving a
Financial Results for Quarter Ended March 31, 2025
- Sales increased by
$70,124 , or25.9% , to$341,264 for the three months of 2025, from$271,140 for the three months of 2024 due to sales of FemaSeed - Research and development expenses increased by
$1,197,741 , or67.6% , to$2,968,472 for the three months of 2025 from$1,770,731 for the three months of 2024 primarily due to increased regulatory costs, material and development costs, and compensation costs - Net loss was
$5,896,839 , or ($0.23) per basic and diluted share attributable to common stockholders, for the three-month period ended March 31, 2025, compared to net loss of$3,599,510 , or ($0.17) per basic and diluted share attributable to common stockholders, for the same period ended March 31, 2024 - Cash and cash equivalents as of March 31, 2025, was approximately
$3.8 million and the Company had an accumulated deficit of approximately$133.1 million . The Company expects, based on its current operating plan, our current cash and cash equivalents, will be sufficient to fund its ongoing operations into early third quarter of 2025.
For more information, please refer to the Company’s Form 10-Q filed May 8, 2025, which can be accessed on the SEC website.
| FEMASYS INC. | ||||||||||||
| Condensed Balance Sheets | ||||||||||||
| (unaudited) | ||||||||||||
| Assets | March 31, 2025 | December 31, 2024 | ||||||||||
| Current assets: | ||||||||||||
| Cash and cash equivalents | $ | 3,820,208 | 3,451,761 | |||||||||
| Accounts receivable, net | 233,598 | 488,373 | ||||||||||
| Inventory | 3,862,188 | 3,046,323 | ||||||||||
| Prepaid and other current assets | 1,216,258 | 1,035,993 | ||||||||||
| Total current assets | 9,132,252 | 8,022,450 | ||||||||||
| Property and equipment, at cost: | ||||||||||||
| Leasehold improvements | 1,238,886 | 1,238,886 | ||||||||||
| Office equipment | 68,530 | 60,921 | ||||||||||
| Furniture and fixtures | 417,876 | 417,876 | ||||||||||
| Machinery and equipment | 3,068,033 | 2,856,740 | ||||||||||
| Construction in progress | 600,551 | 762,445 | ||||||||||
| 5,393,876 | 5,336,868 | |||||||||||
| Less accumulated depreciation | (3,818,451 | ) | (3,740,769 | ) | ||||||||
| Net property and equipment | 1,575,425 | 1,596,099 | ||||||||||
| Long-term assets: | ||||||||||||
| Lease right-of-use assets, net | 1,673,336 | 1,805,543 | ||||||||||
| Intangible assets, net of accumulated amortization | 58,747 | 65,918 | ||||||||||
| Other long-term assets | 838,043 | 954,992 | ||||||||||
| Total long-term assets | 2,570,126 | 2,826,453 | ||||||||||
| Total assets | $ | 13,277,803 | 12,445,002 | |||||||||
| (continued) | ||||||||||||
| FEMASYS INC. | ||||||||||||
| Condensed Balance Sheets | ||||||||||||
| (unaudited) | ||||||||||||
| Liabilities and Stockholders’ Equity | March 31, 2025 | December 31, 2024 | ||||||||||
| Current liabilities: | ||||||||||||
| Accounts payable | $ | 2,331,794 | 1,419,044 | |||||||||
| Accrued expenses | 1,170,288 | 1,151,049 | ||||||||||
| Convertible notes payable, net (including related parties) | 5,762,927 | 5,406,228 | ||||||||||
| Clinical holdback – current portion | 65,946 | 88,581 | ||||||||||
| Lease liabilities – current portion | 510,171 | 517,967 | ||||||||||
| Total current liabilities | 9,841,126 | 8,582,869 | ||||||||||
| Long-term liabilities: | ||||||||||||
| Clinical holdback – long-term portion | 47,140 | 39,611 | ||||||||||
| Lease liabilities – long-term portion | 1,392,820 | 1,518,100 | ||||||||||
| Total long-term liabilities | 1,439,960 | 1,557,711 | ||||||||||
| Total liabilities | 11,281,086 | 10,140,580 | ||||||||||
| Commitments and contingencies | ||||||||||||
| Stockholders’ equity: | ||||||||||||
| Common stock, $.001 par, 200,000,000 authorized, | ||||||||||||
| 27,205,109 shares issued and 27,087,886 outstanding as of | ||||||||||||
| March 31, 2025; and 23,473,149 shares issued | ||||||||||||
| and 23,355,926 outstanding as of December 31, 2024 | 27,205 | 23,473 | ||||||||||
| Treasury stock, 117,223 common shares | (60,000 | ) | (60,000 | ) | ||||||||
| Warrants | 1,860,008 | 1,860,008 | ||||||||||
| Additional paid-in-capital | 133,264,600 | 127,679,198 | ||||||||||
| Accumulated deficit | (133,095,096 | ) | (127,198,257 | ) | ||||||||
| Total stockholders’ equity | 1,996,717 | 2,304,422 | ||||||||||
| Total liabilities and stockholders' equity | $ | 13,277,803 | 12,445,002 | |||||||||
| FEMASYS INC. | ||||||||||||
| Condensed Statements of Comprehensive Loss | ||||||||||||
| (unaudited) | ||||||||||||
| Three Months Ended March 31, | ||||||||||||
| 2025 | 2024 | |||||||||||
| Sales | $ | 341,264 | 271,140 | |||||||||
| Cost of sales (excluding depreciation expense) | 117,266 | 88,532 | ||||||||||
| Operating expenses: | ||||||||||||
| Research and development | 2,968,472 | 1,770,731 | ||||||||||
| Sales and marketing | 908,567 | 300,487 | ||||||||||
| General and administrative | 1,722,713 | 1,502,804 | ||||||||||
| Depreciation and amortization | 84,853 | 71,228 | ||||||||||
| Total operating expenses | 5,684,605 | 3,645,250 | ||||||||||
| Loss from operations | (5,460,607 | ) | (3,462,642 | ) | ||||||||
| Other (expense) income: | ||||||||||||
| Interest income | 19,029 | 224,684 | ||||||||||
| Interest expense | (459,449 | ) | (361,552 | ) | ||||||||
| Total other (expense) income, net | (440,420 | ) | (136,868 | ) | ||||||||
| Loss before income taxes | (5,901,027 | ) | (3,599,510 | ) | ||||||||
| Income tax expense (benefit) | (4,188 | ) | — | |||||||||
| Net loss | $ | (5,896,839 | ) | (3,599,510 | ) | |||||||
| Net loss attributable to common stockholders, basic and diluted | $ | (5,896,839 | ) | (3,599,510 | ) | |||||||
| Net loss per share attributable to common stockholders, basic and diluted | $ | (0.23 | ) | (0.17 | ) | |||||||
| Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted | 25,149,236 | 21,775,357 | ||||||||||
About Femasys
Femasys is a leading biomedical innovator focused on addressing critical unmet needs in women’s health with a broad, patent-protected portfolio of disruptive, accessible, in-office therapeutic and diagnostic products. As a U.S. manufacturer with global regulatory approvals, Femasys is actively commercializing its lead product innovations in the U.S. and key international markets. Femasys’ fertility portfolio includes FemaSeed® Intratubal Insemination, a groundbreaking first-line infertility treatment and FemVue®, a companion diagnostic for fallopian tube assessment. Published clinical trial data show FemaSeed is over twice as effective as traditional IUI, with a comparable safety profile, and high patient and practitioner satisfaction.1
FemBloc® permanent birth control, the first and only non-surgical, in-office alternative to centuries-old surgical sterilization, expects full regulatory approval in Europe mid-year 2025. Commercialization of this highly cost effective, convenient and significantly safer approach, will begin in Spain through engaged partnerships followed by select European countries. Alongside FemBloc, the FemChec®, diagnostic product provides an ultrasound-based test to confirm procedural success. Published data from initial clinical trials demonstrated compelling effectiveness, five-year safety, and high patient and practitioner satisfaction.2 For U.S. FDA approval, enrollment in the FINALE pivotal trial (NCT05977751) is on-going. Learn more at www.femasys.com, or follow us on X, Facebook and LinkedIn.
References
1Liu, J. H., Glassner, M., Gracia, C. R., Johnstone, E. B., Schnell, V. L., Thomas, M. A., L. Morrison, Lee-Sepsick, K. (2024). FemaSeed Directional Intratubal Artificial Insemination for Couples with Male-Factor or Unexplained Infertility Associated with Low Male Sperm Count. J Gynecol Reprod Med, 8(2), 01-12. doi: 10.33140/JGRM.08.02.08.
2Liu, J. H., Blumenthal, P. D., Castaño, P. M., Chudnoff, S. C., Gawron, L. M., Johnstone, E. B., Lee-Sepsick, K. (2025). FemBloc Non-Surgical Permanent Contraception for Occlusion of the Fallopian Tubes. J Gynecol Reprod Med, 9(1), 01-12. doi: 10.33140/JGRM.09.01.05.
Forward-Looking Statements
This press release contains forward-looking statements that are subject to substantial risks and uncertainties. Forward-looking statements can be identified by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “pending,” “intend,” “believe,” “suggests,” “potential,” “hope,” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on our current expectations and are subject to inherent uncertainties, risks and assumptions, many of which are beyond our control, difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, among others: our ability to obtain regulatory approvals for our FemBloc product candidate; develop and advance our current FemBloc product candidate and successfully enroll and complete the clinical trial; the ability of our clinical trial to demonstrate safety and effectiveness of our product candidate and other positive results; estimates regarding the total addressable market for our products and product candidate; our ability to commercialize our products and product candidate, our ability to establish, maintain, grow or increase sales and revenues, or the effect of delays in commercializing our products, including FemaSeed; our business model and strategic plans for our products, technologies and business, including our implementation thereof; and those other risks and uncertainties described in the section titled "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Femasys undertakes no duty to update such information except as required under applicable law.
Contacts:
Investors:
IR@femasys.com
Media:
Media@femasys.com
FAQ
What were FEMY's Q1 2025 financial results?
What major regulatory approvals did Femasys (FEMY) receive in Q1 2025?
How much cash does FEMY have and how long will it last?
What was the sales growth for Femasys's FemaSeed product in Q1 2025?
What strategic partnerships did FEMY announce in Q1 2025?
